Shares of Krsnaa Diagnostics Ltd. are trading flat after reaching a day’s high of Rs 902.40 on 11th October. This follows the firm’s announcement that it has secured two agreements with the Ranchi Institute of Neuro-Psychiatry & Allied Services (RINPAS) and the Medical Superintendent of Sadar Hospital, Ranchi.

The company has established its first agreement with the Ranchi Institute of Neuro-Psychiatry & Allied Services (RINPAS) to supply, install, commission, operate, and maintain a radiology centre (CT & MRI) and pathology laboratory services on a public-private partnership (PPP) basis.

In a related development, the firm has also secured a signed agreement from the Medical Superintendent of Sadar Hospital, Ranchi. This contract covers commissioning, installing, operating, and maintaining radiology services (CT and MRI) at Sadar Hospital, located on Purulia Road, Ranchi.

Similar to the RINPAS agreement, the initiative with Sadar Hospital will also operate under a public-private partnership (PPP) framework. Due to their newness, the financial size of both contracts cannot be estimated yet.

In 2024, Krsnaa Diagnostics’s shares surged by nearly 22%. The company’s market capitalisation stands at around Rs 2,770 crore.

At 2:09 PM, the shares of Krsnaa Diagnostics were trading 0.35% lower at Rs 856.80 on NSE.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!